UniProt ID | GNA13_HUMAN | |
---|---|---|
UniProt AC | Q14344 | |
Protein Name | Guanine nucleotide-binding protein subunit alpha-13 | |
Gene Name | GNA13 | |
Organism | Homo sapiens (Human). | |
Sequence Length | 377 | |
Subcellular Localization |
Cell membrane Lipid-anchor . Melanosome . Cytoplasm . Nucleus . Identified by mass spectrometry in melanosome fractions from stage I to stage IV (PubMed:17081065). Detected in the cytoplasm of Leydig cells and in the seminiferous epithelium, includ |
|
Protein Description | Guanine nucleotide-binding proteins (G proteins) are involved as modulators or transducers in various transmembrane signaling systems. [PubMed: 15240885] | |
Protein Sequence | MADFLPSRSVLSVCFPGCLLTSGEAEQQRKSKEIDKCLSREKTYVKRLVKILLLGAGESGKSTFLKQMRIIHGQDFDQRAREEFRPTIYSNVIKGMRVLVDAREKLHIPWGDNSNQQHGDKMMSFDTRAPMAAQGMVETRVFLQYLPAIRALWADSGIQNAYDRRREFQLGESVKYFLDNLDKLGEPDYIPSQQDILLARRPTKGIHEYDFEIKNVPFKMVDVGGQRSERKRWFECFDSVTSILFLVSSSEFDQVLMEDRLTNRLTESLNIFETIVNNRVFSNVSIILFLNKTDLLEEKVQIVSIKDYFLEFEGDPHCLRDVQKFLVECFRNKRRDQQQKPLYHHFTTAINTENIRLVFRDVKDTILHDNLKQLMLQ | |
Overview of Protein Modification Sites with Functional and Structural Information | ||
|
* ASA = Accessible Surface Area
Locations | Modification | Substrate Peptides & Secondary Structure |
ASA (%) | Reference | Orthologous Protein Cluster |
---|---|---|---|---|---|
9 | Phosphorylation | ADFLPSRSVLSVCFP CCCCCCCHHHHHCCC | 31.57 | 28111955 | |
12 | Phosphorylation | LPSRSVLSVCFPGCL CCCCHHHHHCCCCCC | 18.06 | 28111955 | |
14 | S-palmitoylation | SRSVLSVCFPGCLLT CCHHHHHCCCCCCCC | 2.83 | 10747909 | |
18 | S-palmitoylation | LSVCFPGCLLTSGEA HHHCCCCCCCCCCHH | 2.61 | 10747909 | |
21 | Phosphorylation | CFPGCLLTSGEAEQQ CCCCCCCCCCHHHHH | 23.03 | 28111955 | |
22 | Phosphorylation | FPGCLLTSGEAEQQR CCCCCCCCCHHHHHH | 34.31 | 28111955 | |
31 | Phosphorylation | EAEQQRKSKEIDKCL HHHHHHHHHHHHHHH | 37.40 | 28111955 | |
36 | Ubiquitination | RKSKEIDKCLSREKT HHHHHHHHHHHCCHH | 42.61 | - | |
43 | Phosphorylation | KCLSREKTYVKRLVK HHHHCCHHHHHHHHH | 28.88 | 20068231 | |
44 | Phosphorylation | CLSREKTYVKRLVKI HHHCCHHHHHHHHHH | 18.29 | 20068231 | |
59 | Phosphorylation | LLLGAGESGKSTFLK HHHCCCCCCHHHHHH | 51.07 | 20068231 | |
61 | Ubiquitination | LGAGESGKSTFLKQM HCCCCCCHHHHHHHH | 56.45 | - | |
66 | Ubiquitination | SGKSTFLKQMRIIHG CCHHHHHHHHHHHHC | 37.55 | - | |
87 | Phosphorylation | AREEFRPTIYSNVIK HHHHHHHHHHHHHHC | 28.43 | 20068231 | |
88 | Ubiquitination | REEFRPTIYSNVIKG HHHHHHHHHHHHHCC | 3.83 | - | |
90 | Phosphorylation | EFRPTIYSNVIKGMR HHHHHHHHHHHCCCE | 22.29 | 20068231 | |
105 | Ubiquitination | VLVDAREKLHIPWGD EEEECHHHCCCCCCC | 39.55 | - | |
119 | Ubiquitination | DNSNQQHGDKMMSFD CCCCCCCCCEECCCC | 31.71 | 21906983 | |
124 | Ubiquitination | QHGDKMMSFDTRAPM CCCCEECCCCCCCHH | 19.24 | - | |
131 | Sulfoxidation | SFDTRAPMAAQGMVE CCCCCCHHHHCCCHH | 4.75 | 21406390 | |
183 | Ubiquitination | YFLDNLDKLGEPDYI HHHHCHHHCCCCCCC | 62.65 | 21890473 | |
189 | Phosphorylation | DKLGEPDYIPSQQDI HHCCCCCCCCCHHHE | 26.00 | - | |
190 | Ubiquitination | KLGEPDYIPSQQDIL HCCCCCCCCCHHHEE | 3.27 | 21890473 | |
203 | Phosphorylation | ILLARRPTKGIHEYD EEECCCCCCCCEECC | 39.84 | 12399457 | |
204 | Malonylation | LLARRPTKGIHEYDF EECCCCCCCCEECCE | 59.56 | 26320211 | |
204 | Ubiquitination | LLARRPTKGIHEYDF EECCCCCCCCEECCE | 59.56 | - | |
214 | Ubiquitination | HEYDFEIKNVPFKMV EECCEEEECCCCEEE | 44.70 | 21890473 | |
214 | Ubiquitination | HEYDFEIKNVPFKMV EECCEEEECCCCEEE | 44.70 | 21890473 | |
219 | Ubiquitination | EIKNVPFKMVDVGGQ EEECCCCEEEECCCC | 31.76 | - | |
262 | Phosphorylation | VLMEDRLTNRLTESL HHCHHHHHHHHHHHH | 21.13 | 26074081 | |
266 | Phosphorylation | DRLTNRLTESLNIFE HHHHHHHHHHHCHHH | 21.94 | 26074081 | |
268 | Phosphorylation | LTNRLTESLNIFETI HHHHHHHHHCHHHHH | 22.83 | 26074081 | |
268 | Ubiquitination | LTNRLTESLNIFETI HHHHHHHHHCHHHHH | 22.83 | - | |
274 | Phosphorylation | ESLNIFETIVNNRVF HHHCHHHHHHHCCCC | 21.34 | 26074081 | |
277 | Ubiquitination | NIFETIVNNRVFSNV CHHHHHHHCCCCCCC | 27.09 | - | |
285 | Phosphorylation | NRVFSNVSIILFLNK CCCCCCCEEEEEECC | 14.25 | - | |
363 | Ubiquitination | RLVFRDVKDTILHDN EEEEECHHHHHHCHH | 54.14 | - | |
363 | Acetylation | RLVFRDVKDTILHDN EEEEECHHHHHHCHH | 54.14 | 7695247 | |
363 | Malonylation | RLVFRDVKDTILHDN EEEEECHHHHHHCHH | 54.14 | 26320211 | |
372 | Ubiquitination | TILHDNLKQLMLQ-- HHHCHHHHHHHCC-- | 47.87 | 21890473 | |
372 | Acetylation | TILHDNLKQLMLQ-- HHHCHHHHHHHCC-- | 47.87 | 7695257 |
Modified Location | Modified Residue | Modification | Type of Upstream Proteins | Gene Name of Upstream Proteins | UniProt AC of Upstream Proteins | Sources |
---|---|---|---|---|---|---|
203 | T | Phosphorylation | Kinase | PRKACA | P17612 | GPS |
203 | T | Phosphorylation | Kinase | PKA-FAMILY | - | GPS |
203 | T | Phosphorylation | Kinase | PKA | - | Uniprot |
203 | T | Phosphorylation | Kinase | PKA_GROUP | - | PhosphoELM |
Modified Location | Modified Residue | Modification | Function | Reference |
---|---|---|---|---|
203 | T | Phosphorylation |
| 12399457 |
* Distance = the distance between SAP position and PTM sites.
Modified Location | Modification | Variant Position (Distance <= 10) |
Residue Change | SAP | Related Disease | Reference |
---|---|---|---|---|---|---|
Oops, there are no SNP-PTM records of GNA13_HUMAN !! |
Interacting Protein | Gene Name | Interaction Type | PPI Reference | Domain-Domain Interactions |
---|---|---|---|---|
AKAP3_HUMAN | AKAP3 | physical | 11696326 | |
ARHG1_HUMAN | ARHGEF1 | physical | 12681510 | |
ARHG1_HUMAN | ARHGEF1 | physical | 9641916 | |
RADI_HUMAN | RDX | physical | 10816569 | |
FAK2_HUMAN | PTK2B | physical | 10821841 | |
KAP2_HUMAN | PRKAR2A | physical | 11696326 | |
ARHGC_HUMAN | ARHGEF12 | physical | 11094164 | |
PAR1_HUMAN | F2R | physical | 8290554 | |
TA2R_HUMAN | TBXA2R | physical | 8290554 | |
ARHGB_HUMAN | ARHGEF11 | physical | 10026210 | |
M3K5_HUMAN | MAP3K5 | physical | 17595347 | |
ARG28_HUMAN | ARHGEF28 | physical | 17595347 | |
AIP_HUMAN | AIP | physical | 19390533 | |
CXCR5_HUMAN | CXCR5 | physical | 23773523 | |
CXCR4_HUMAN | CXCR4 | physical | 23773523 | |
PAR1_HUMAN | F2R | physical | 23773523 |
Kegg Disease | ||||||
---|---|---|---|---|---|---|
There are no disease associations of PTM sites. | ||||||
OMIM Disease | ||||||
There are no disease associations of PTM sites. | ||||||
Kegg Drug | ||||||
There are no disease associations of PTM sites. | ||||||
DrugBank | ||||||
There are no disease associations of PTM sites. |
loading...
Palmitoylation | |
Reference | PubMed |
"Galpha 13 requires palmitoylation for plasma membrane localization,Rho-dependent signaling, and promotion of p115-RhoGEF membranebinding."; Bhattacharyya R., Wedegaertner P.B.; J. Biol. Chem. 275:14992-14999(2000). Cited for: PALMITOYLATION AT CYS-14 AND CYS-18, AND MUTAGENESIS OF CYS-14 ANDCYS-18. | |
Phosphorylation | |
Reference | PubMed |
"PKA-mediated phosphorylation of Galpha 13 switch I region alters theGalpha beta gamma 13-GPCR complex and inhibits Rho activation."; Manganello J.M., Huang J.-S., Kozasa T., Voyno-Yasenetskaya T.A.,Le Breton G.C.; J. Biol. Chem. 278:124-130(2003). Cited for: PHOSPHORYLATION AT THR-203, AND MUTAGENESIS OF THR-203. |